BIOMERICA INC BMRA revenue by segment, product and geography
In its fiscal year ending 2026-05-31, BIOMERICA INC reported revenue across 4 products and services; the largest, Clinical Lab, was $2.73M, 61.4% of the filed sum (-14.1% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Clinical Lab$2.73M61.4%-14.1% yoy
- Contract Manufacturing$891K20.0%-16.7% yoy
- Over The Counte$821K18.4%-21.7% yoy
- Physicians Office$9K0.2%-18.2% yoy
Members sum to the consolidated $4.45M for this period.
- North America$1.47M32.9%-11.6% yoy
- Asia$1.41M31.6%-18.0% yoy
- Europe$1.12M25.1%-13.9% yoy
- Middle East$446K10.0%-29.2% yoy
- South America$15K0.3%+87.5% yoy
Members sum to the consolidated $4.45M for this period.
- Clinical Lab$621K62.9%no prior
- Over The Counte$197K20.0%no prior
- Contract Manufacturing$167K16.9%no prior
- Physicians Office$2K0.2%no prior
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.